Amoxicillin 250 mg +Clavulanic acid 62.5 mg tablet
Treatment of skin infections, urinary tract infections, respiratory tract infections, gastrointestinal tract infections and infections of the oral cavity in dogs
COMPOSITION
Each tablet contains:
Amoxicillin (as amoxicillin trihydrate) 250 mg
Clavulanic acid (as potassium clavulanate) 62.5 mg
Indications for use, specifying the target species
Treatment of infections in dogs caused by bacteria sensitive to amoxicillin in combination with clavulanic acid, particularly:Skin infections (including superficial and deep pyodermas) associated with Staphylococci (including beta-lactamase producing strains) and Streptococci.
Urinary tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci, Escherichia coli (including beta-lactamase producing strains), Fusobacterium necrophorum and Proteus spp.
Respiratory tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci and Pasteurellae.
Gastrointestinal tract infections associated with Escherichia coli (including beta-lactamase producing strains) and Proteus spp.
Infections of the oral cavity (mucous membrane) associated with Clostridia, Corynebacteria, Staphylococci (including beta-lactamase producing strains), Streptococci, Bacteroides spp (including beta-lactamase producing strains), Fusobacterium necrophorum and Pasteurellae.
Dosage
The recommended dose is 12.5 mg of combined active substance (=10 mg amoxicillin and 2.5 mg clavulanic acid) per kg bodyweight, twice daily.
The following table is intended as a guide to dispensing the product at the standard dose rate of 12.5 mg of combined actives per kg bodyweight twice daily.
In refractory cases of skin infections, a double dose is recommended (25 mg per kg bodyweight, twice daily).
Pharmacodynamic properties
Amoxicillin/clavulanate has a wide range of activity which includes βlactamase producing strains of both Gram-positive and Gram-negative aerobes, facultative anaerobes and obligate anaerobes.
Good susceptibility is shown with several gram-positive bacteria including Staphylococci (including beta-lactamase producing strains, MIC90 0.5 μg/ml), Clostridia (MIC90 0.5 μg/ml), Corynebacteria and Streptococci, and gram-negative bacteria including Bacteroides spp (including betalactamase producing strains, MIC90 0.5 μg/ml), Pasteurellae (MIC90 0.25 μg/ml), Escherichia coli (including beta-lactamase producing strains, MIC90 8 μg/ml) and Proteus spp (MIC90 0.5 μg/ml). Variable susceptibility is found in some E. coli.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life of tablet quarters: 12 hours.
Special precautions for storage
Do not store above 25°C.
Store in the original container.
Quarter tablets should be returned to the opened strip and stored in a refrigerator.